Active Filter(s):
Details:
In the trial, CPL’280 was administered orally in single and multiple ascending doses in healthy volunteers to assess safety and pharmacokinetic parameters (PK). Pharmacokinetic interactions with metformin and food were also tested.
Lead Product(s): CPL’280
Therapeutic Area: Endocrinology Product Name: CPL’280
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2021